Our Firm has been monitoring this trial very closely, as its outcome could provide clues as to how juries might rule in similar Actos lawsuits.
New York, New York (PRWEB) September 26, 2013
Actos lawsuits (http://www.consumerinjurylawyers.com/actos/Actos-Lawsuit.html) involving allegations that long-term use of the medication caused patients to develop bladder cancer continue to move forward in courts across the country, Bernstein Liebhard LLP reports. According to court documents, closing arguments have been delivered in the nation’s second trial of an Actos bladder cancer lawsuit, and jury deliberations are now underway in Maryland state court. (An v. Nieberlein, 24-C12003565, Circuit Court for the City of Baltimore, State of Maryland.)
“Our Firm has been monitoring this trial very closely, as its outcome could provide clues as to how juries might rule in similar Actos lawsuits. We hear from Actos users on a regular basis who worry that their long-term use of the Type 2 diabetes drug may have caused their bladder cancer,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free lawsuit evaluations to alleged victims of Actos bladder cancer.
Actos Bladder Cancer Litigation
According to court documents, the Actos lawsuit underway in Maryland was filed on behalf of a Vietnamese immigrant who died of bladder cancer last year. During yesterday’s closing arguments, the attorney representing the man’s family told the jury that Takeda Pharmaceuticals should be held liable because the company only issued an Actos bladder cancer warning in 2011, even though company officials had been aware of evidence linking long-term use of the drug to bladder cancer for years.
Actos lawsuits have been mounting since June 2011, when the U.S. Food & Drug Administration (FDA) warned that use of Actos for one year or more had been linked to the development of bladder cancer. According to court documents, more than 2,500 Actos lawsuits involving bladder cancer lawsuits are pending in a multidistrict litigation underway in U.S. District Court, Western District of Louisiana. That litigation’s first bellwether trial will begin on January 27, 2014, while the second will commence on April 14, 2014. (In re: Actos Product Liability Litigation, MDL No. 2299)
The nation’s first trial involving Actos and bladder cancer concluded this past April in Los Angeles Superior court, with that jury awarding more than $6 million to a man who was diagnosed with bladder cancer after taking Actos for four years. However, the judge overseeing the case granted Takeda Pharmaceuticals’ request to set aside the verdict. According to court documents, the man’s family has filed an appeal. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)
Actos patients who developed bladder cancer after using the drug for a year or more may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn More about the ongoing Actos bladder cancer litigation by visiting Bernstein Liebhard LLP’s website. For additional information, please contact Bernstein Liebhard LLP today by calling 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP